Skip to content
Screener

Open Text OTEX Research and development expense

Research and development expense at other companies

COA
Hemab Therapeutics Holdings, Inc.COAG
$3.51M-23.2%
COA
Hemab Therapeutics Holdings, Inc.COAG
$5.8M-2.7%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$71.1M-3.4%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$1.9M+11.8%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$36K-99.5%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$9.36M+31.7%

Other financials

Income statement

See full
Revenue$1.3B+2.9%
Gross profit$1.0B+6.7%
Operating income$319.7M+76.1%
Net income$155.7M+440%
EPS (diluted)$0.64+433%

Balance sheet

See full
Cash & equivalents$956.0M-17.4%
Total debt$6.0B-10.1%
Total equity$4.0B+2.2%
Total assets$13.1B-4.8%

Cash flow

See full
Operating cash flow$185.8M+17.5%
CapEx$63.8M+86.5%
Free cash flow$122.0M-1.6%

Valuation

See full
Market cap$6.21B-17.2%
Enterprise value$11.23B-13.6%
P/E9.7×-7.5×
P/S1.2×-0.3×

Profitability

See full
Gross margin73.7%+1.5pp
Operating margin20.6%+3.4pp
Net margin12.3%+3.8pp
FCF margin15.4%+2.1pp

Returns & leverage

See full
Return on equity16.2%+5.5pp
Debt / equity1.5×-0.2×
Current ratio0.8×0.0×

Where this comes from

Reported directly by Open Text in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Open Text’s 10-K, filed August 6, 2026.

Filed
Aug 6, 2026, 7:08 AM EDT
Fiscal year
FY2026
Accession
0001002638-26-000068
Line itemYear Ended June 30, 2026Year Ended June 30, 2025Year Ended June 30, 2024
Total cost of revenues1,377,9401,434,1181,578,549
Gross profit3,868,4613,734,2874,191,028
Operating expenses:
Research and development647,707755,936864,463
Sales and marketing1,136,0301,059,4971,163,134
General and administrative436,566427,811577,038
Depreciation143,938130,573131,599
Amortization of acquired customer-based intangible assets (Note 8)288,603321,891432,404

Item 15. Exhibits and Financial Statement Schedules

FAQ

What is Open Text's research and development expense?
Open Text (OTEX) reported research and development expense of $149.1M in Q2 2026.
How has Open Text's research and development expense changed year-over-year?
Open Text's research and development expense decreased by 20.3% year-over-year, from $187.18M to $149.1M.
What is the long-term trend for Open Text's research and development expense?
Over 4 years (2022 to 2026), Open Text's research and development expense has grown at a 10.1% compound annual growth rate (CAGR), from $440.45M to $647.71M.
What does research and development expense mean?
Research and development expense

Ask your AI about Open Text's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude